Cellular immunotherapies for cancer
Berraondo P (1,2,3), Labiano S (1,2), Minute L (1,2), Etxeberria I (1,2), Vasquez M (1,2), Sanchez-Arraez A (1,2), Teijeira A (1,2,3), Melero I (1,2,3,4).
(1) Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.
(2) Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
(3) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain.
(4) Servicio de Inmunología e Inmunoterapia, Clínica Universidad de Navarra, Pamplona, Spain.
Lessons learned over decades on the use of gene and cell therapies have found clinical applicability in the field of cancer immunotherapy.
On December 16th, 2016 a symposium was held in Pamplona (Spain) to analyze and discuss the critical points for the clinical success of adoptive cell transfer strategies in cancer immunotherapy.
Cellular immunotherapy is being currently exploited for the development of new cancer vaccines using ex vivo manipulated dendritic cells or to enhance the number of effector cells, transferring reinvigorated NK cells or T cells.
In this meeting report, we summarize the main topics covered and provide an overview of the field of cellular immunotherapy.
CITA DEL ARTÍCULO Oncoimmunology. 2017 May 2;6(5):e1306619. doi: 10.1080/2162402X.2017.1306619